What do investors think about antibiotics companies? Not much. Paratek, at a price of just $5.42 has a 36% short ratio. That is, 36% of tradable shares are being shorted by skeptical investors.
News and analysis on drug development, clinical evidence, regulatory approvals, pharmacology, and the science behind treatments — from small molecules to biologics.
